Sight Sciences Q3 revenue up 7% to $20.0M, withdraws FY 2023 guidance on LCD uncertainty

Sight Sciences, Inc.

2023-Q3 EPS reported -$0.92 revenue$62,305,000

Q3 revenue $20.0M (+7% YoY); Surgical Glaucoma $18.4M (+8% YoY); Dry Eye $1.6M (-1% YoY).
Net loss $13.0M ($0.27 per share) vs $22.2M ($0.46) a year ago; gross margin 86.6% (vs 84.3%).
Withdraws full-year 2023 revenue and adjusted operating expense guidance due to WPS LCD uncertainty.
Implements ~10% RIF expecting $7.9M annualized savings; other cost initiatives ~$5.0M annual savings.
Appointed Matt Link as Chief Commercial Officer; GEMINI 2 study shows sustained IOP reduction at 36 months.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sight Sciences, Inc. reported third quarter ended September 30, 2023 results: revenue $20.0 million.

Period: third quarter ended September 30, 2023
Revenue: $20.0 million
Result: reported results

Exact text from the filing

the third quarter ended September 30, 2023 and withdrew its guidance for full year 2023. Recent Business and Financial Highlights • Generated third quarter 2023 total revenue of $20.0 million, an increase of 7% compared to the same period in the prior year. • Achieved total gross margin of 86.6% in the third quarter of 2023 compared to 84.3% in the same period in the

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Sight Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-060293

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.